Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Year-over-year earnings per share growth rate
Percentile
P36
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -62.10% |
| Q3 2025 | 2296.00% |
| Q2 2025 | 111.31% |
| Q1 2025 | -34.76% |
| Q4 2024 | -320.51% |
| Q3 2024 | 86.46% |
| Q2 2024 | -159.26% |
| Q1 2024 | 367.31% |
| Q4 2023 | 240.54% |
| Q3 2023 | -669.23% |
| Q2 2023 | -94.72% |
| Q1 2023 | 336.54% |
| Q4 2022 | -5300.00% |
| Q3 2022 | 140.00% |
| Q2 2022 | 94.51% |
| Q1 2022 | -203.33% |
| Q4 2021 | -136.59% |
| Q3 2021 | -55.43% |
| Q2 2021 | 67.27% |
| Q1 2021 | 205.56% |
| Q4 2020 | 185.71% |
| Q3 2020 | -130.43% |
| Q2 2020 | 194.52% |
| Q1 2020 | -239.53% |
| Q4 2019 | 46.91% |
| Q3 2019 | -9.46% |
| Q2 2019 | -102.27% |
| Q1 2019 | 1713.37% |
| Q4 2018 | -163.32% |
| Q3 2018 | -7.54% |
| Q2 2018 | 61.97% |
| Q1 2018 | 726.47% |
| Q4 2017 | -185.00% |
| Q3 2017 | 37.93% |
| Q2 2017 | 20.83% |
| Q1 2017 | 260.00% |
| Q4 2016 | -587.01% |
| Q3 2016 | 111.00% |
| Q2 2016 | -187.50% |
| Q1 2016 | 0.00% |